Jeffrey Newcorn, MD
- PROFESSOR | Psychiatry
- PROFESSOR | Pediatrics
Specialties:Psychiatry, Child and Adolescent Psychiatry
Dr. Jeffrey Newcorn received his medical degree from the University of Rochester in New York (1977). He completed his general psychiatry (1980) and child and adolescent psychiatry (1982) training at Tufts-New England Medical Center, Boston. Dr. Newcorn is currently professor of psychiatry and pediatrics, and director, Division of ADHD and Learning Disorders at Icahn School of Medicine at Mount Sinai. He is also the director of Pediatric Psychopharmacology for the Mount Sinai Health System, and supervising psychiatrist in the Student Trainee Mental Health Program at Mount Sinai.
Dr. Newcorn is a highly regarded clinician - researcher with special expertise in the areas of ADHD, aggression, descriptive psychopathology of child and adolescent disorders, and child and adolescent psychopharmacology, whose academic work spans both clinical and translational topics. He has been a member of the steering committee of the NIMH-funded multicenter study “Multimodal Treatment of Children with ADHD (MTA) (serving as chair in 2000).” He was the principal investigator on an NIMH-funded ADHD Research Infrastructure Network devoted to understanding the neurobiology of ADHD, and has been (and currently is) the principal investigator or co-investigator on several NIH-funded and industry-funded grants which examine the clinical presentation and neurobiological basis of ADHD and its treatment. He directs an active clinical trials program, and has studied many of the newer medication treatments for ADHD. He has published over 350 articles and chapters in textbooks on these and related subjects. Dr. Newcorn’s most recent research focuses on the clinical and neurobiological basis of differential response to ADHD treatments, utilizing data obtained from clinical, pharmacogenetic and fMRI measures, as well as the neurobiological basis of substance abuse risk in individuals with ADHD.
Dr. Newcorn is an internationally recognized educator and mentor, and is an editorial board member of several leading child psychiatry/psychology and psychopharmacology journals. He was chair of the American Academy of Child and Adolescent Psychiatry Committee on Training and Education (2002-2005), and has been recognized several times for his role in mentorship by the American Academy of Child and Adolescent Psychiatry. Dr. Newcorn has held several prominent positions in US and international organizations. He was a member of the child psychiatry working group for DSM-IV, and a consultant to the American Psychiatric Association DSM for primary care. He is a founding member of the board of directors of the American Professional Society for ADHD and Related Disorders (APSARD) (currently serving as president), and chair of the advisory board of the Klingenstein Third Generation Foundation (since 2008). He has had a major role in organizing scientific meetings for ADHD worldwide, having served as chair of the APSARD program committee (2014-2018),the scientific program committee for the World Federation of ADHD 5th (Glasgow, 2015), 6th (Vancouver, 2018) and 7th (Prague, 2021) International Congresses, and the program committee for the 2nd and 3rd International Symposia on ADHD in Tel Aviv.
Dr. Newcorn has received numerous awards for his work, including the Hulse Award for lifetime achievement from the New York Council on Child and Adolescent Psychiatry (2002), the 4D Technology Development Award from Mount Sinai (2015), and the Elaine Schlosser Lewis Award for Research in Attention Deficit Disorder (2018). He was elected to the CHADD Hall of Fame in 2014.
Am Board of Psychiatry & Neurology (Sub: Child)
Psychiatry, American Board of Psychiatry and Neurology
- Attention Deficit Hyperactivity Disorder And Attention Deficit Disorder
MD, University of Rochester School of Medicine & Dentistry
Residency, Clinical Psychiatry, New England Medical Center
Residency, Clinical Psychiatry, New England Medical Center
Fellowship, Child Psychiatry, New England Medical Center
Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, Logan J, Ma Y, Schulz K, Pradhan K, Wong C, Swanson JM. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Archives of general psychiatry 2007 Aug; 64(8).
Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. The American journal of psychiatry 2008 Jun; 165(6).
Schulz KP, Clerkin SM, Halperin JM, Newcorn JH, Tang CY, Fan J. Dissociable neural effects of stimulus valence and preceding context during the inhibition of responses to emotional faces. Human brain mapping 2009 Sep; 30(9).
Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA : the journal of the American Medical Association 2009 Sep; 302(10).
Clerkin SM, Schulz KP, Halperin JM, Newcorn JH, Ivanov I, Tang CY, Fan J. Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals. Biological psychiatry 2009 Aug; 66(4).
Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, D'souza DN, Schuh LM, Allen AJ. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2009 Dec; 48(12).
Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. Journal of the American Academy of Child and Adolescent Psychiatry 2009 May; 48(5).
Solanto MV, Schulz KP, Fan J, Tang CY, Newcorn JH. Event-related FMRI of inhibitory control in the predominantly inattentive and combined subtypes of ADHD. Journal of neuroimaging : official journal of the American Society of Neuroimaging 2009 Jul; 19(3).
Bédard AC, Schulz KP, Cook EH, Fan J, Clerkin SM, Ivanov I, Halperin JM, Newcorn JH. Dopamine transporter gene variation modulates activation of striatum in youth with ADHD. NeuroImage 2010 Nov; 53(3).
Volkow ND, Wang GJ, Newcorn JH, Kollins SH, Wigal TL, Telang F, Fowler JS, Goldstein RZ, Klein N, Logan J, Wong C, Swanson JM. Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. Molecular psychiatry 2010 Sep;.